Technical Analysis for MTSR - Metsera, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | N/A | N/A |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week High | Strength | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Gapped Down | Weakness | 0.00% | |
New 52 Week Closing High | Bullish | -0.10% | |
Gapped Up | Strength | -0.10% | |
Up 3 Days in a Row | Strength | -0.10% | |
Up 4 Days in a Row | Strength | -0.10% | |
New 52 Week Closing High | Bullish | 0.85% | |
Up 3 Days in a Row | Strength | 0.85% | |
Gapped Down | Weakness | 0.85% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 2 days ago |
New 52 Week High | 2 days ago |
Up 2% | 2 days ago |
Up 1% | 2 days ago |
Reversed from Down | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: Unknown
Metsera, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight, and related metabolic conditions. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera is headquartered in New York City. The company’s lead candidate, MET-097i, is an ultra-long-acting GLP-1 receptor agonist designed for potential once-monthly, titration-free subcutaneous injection. In a 12-week Phase 2a clinical trial, MET-097i demonstrated an average weight loss of 11.3% in participants with obesity and overweight, without Type 2 diabetes, and exhibited a favorable safety profile.
Keywords: Biotechnology Diabetes Obesity Peptide Hormones GLP-1 Poly Agonist Peptides Glucagon Like Peptide 1 Peptide Therapeutics Treatment Of Obesity
Classification
Keywords: Biotechnology Diabetes Obesity Peptide Hormones GLP-1 Poly Agonist Peptides Glucagon Like Peptide 1 Peptide Therapeutics Treatment Of Obesity
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 30.26 |
52 Week Low | 25.06 |
Average Volume | 1,005,341 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 0.00 |
10-Day Moving Average | 0.00 |
Average True Range | 0.00 |
RSI (14) | 0.00 |
ADX | 0.0 |
+DI | 0.00 |
-DI | 0.00 |
Chandelier Exit (Long, 3 ATRs) | N/A |
Chandelier Exit (Short, 3 ATRs) | N/A |
Upper Bollinger Bands | 0.00 |
Lower Bollinger Band | 0.00 |
Percent B (%b) | 0.0 |
BandWidth | 0.00 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 31.74 | ||||
Resistance 3 (R3) | 31.74 | 31.00 | 31.36 | ||
Resistance 2 (R2) | 31.00 | 30.43 | 31.00 | 31.24 | |
Resistance 1 (R1) | 30.25 | 30.08 | 30.63 | 30.25 | 31.11 |
Pivot Point | 29.51 | 29.51 | 29.70 | 29.51 | 29.51 |
Support 1 (S1) | 28.76 | 28.94 | 29.14 | 28.76 | 27.89 |
Support 2 (S2) | 28.02 | 28.59 | 28.02 | 27.76 | |
Support 3 (S3) | 27.27 | 28.02 | 27.64 | ||
Support 4 (S4) | 27.27 |